Trials / Recruiting
RecruitingNCT06417554
A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors
A Phase IB /II, Multicenter, Open-Label Study of Safety, Tolerability and Efficacy of SHR-A2102 for Injection With or Without Antitumor Therapy in Subjects With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 for injection with or without Antitumor Therapy in Advanced Solid Tumors. To explore the reasonable dosage of SHR-A2102 for Advanced Solid Tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-A2102 | SHR-A2102 |
| DRUG | SHR-A2102 ; Adebrelimab injection | SHR-A2102 + Adebrelimab injection |
Timeline
- Start date
- 2024-05-13
- Primary completion
- 2027-07-01
- Completion
- 2027-07-01
- First posted
- 2024-05-16
- Last updated
- 2024-12-31
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06417554. Inclusion in this directory is not an endorsement.